C4 Therapeutics

CCCC · NASDAQ🇺🇸

Overview

Earnings Dividends Seasonality Metrics

Reported earnings about 1 month ago

Total Revenue

$7.24M

Previous year: $3.04M

+138.2%

EPS

-$0.37

Previous year: -$0.41

-9.8%

Research and development expense

$27.1M

General and administrative expense

$9.33M

Total operating expenses

Loading...

C4 Therapeutics

Unlock previous datapoints

Upgrade

C4 Therapeutics

Unlock previous datapoints

Upgrade

C4 Therapeutics Revenue by Segment

Revenue by Segment

Collaboration agreements Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

MKDG Agreement Revenue

CapyFin.com

Merck Agreement Revenue

CapyFin.com

Betta Agreement Revenue

CapyFin.com

Roche Agreement Revenue

CapyFin.com

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$235M

P/E Ratio

-1.60

Sector

N/A

Industry

N/A

52-Week High

$3.58

52-Week Low

$1.08

Research and development expense

$27.1M

General and administrative expense

$9.33M

Total operating expenses

$36.4M

Weighted-average shares outstanding

70.83M

Interest and other income, net

$2.84M

Products

Get in Touch

Resources

C4 Therapeutics

C4 Therapeutics

C4 Therapeutics

C4 Therapeutics Revenue by Segment

Revenue by Segment

Collaboration agreements Revenue

MKDG Agreement Revenue

Merck Agreement Revenue

Betta Agreement Revenue

Roche Agreement Revenue

Historical Earnings Impact

Avg. Return Before/After Earnings

Key Statistics